Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Sarepta Therapeutics is a precision genetic medicine company focused on rare neuromuscular diseases, primarily Duchenne muscular dystrophy (DMD). The company commercializes four exon-skipping therapies (EXONDYS 51, VYONDYS 53, AMONDYS 45, and CASIMERSEN) targeting specific DMD mutations, alongside ELEVIDYS, a gene therapy approved for ambulatory DMD patients aged 4-5. With 83% gross margins and recent profitability, Sarepta has transitioned from pure R&D to a commercial-stage biotech with significant revenue concentration in rare disease treatments.
Sarepta generates revenue through ultra-high-priced precision therapies for rare genetic diseases with limited patient populations. ELEVIDYS, a one-time gene therapy, commands pricing around $3.2 million per patient, while exon-skipping therapies require chronic administration at approximately $300,000-500,000 annually per patient. Pricing power derives from orphan drug exclusivity, lack of direct competition for mutation-specific treatments, and high unmet medical need. The company targets approximately 3,000-5,000 treatable DMD patients in the US across its portfolio. Revenue scales through label expansions (ELEVIDYS recently expanded to non-ambulatory patients), international launches, and pipeline progression into limb-girdle muscular dystrophies.
ELEVIDYS label expansion decisions and commercial uptake metrics (patient starts, duration of effect data)
Clinical trial readouts for pipeline assets (SRP-9001 in LGMD2E, SRP-5051 for additional DMD mutations)
Regulatory approvals and reimbursement decisions in ex-US markets (EU, Japan for ELEVIDYS)
Real-world evidence data on gene therapy durability and safety (5-year+ follow-up results)
Manufacturing capacity announcements and supply chain execution for gene therapy production
Gene therapy durability uncertainty - ELEVIDYS efficacy beyond 5 years remains unproven, creating risk of re-dosing requirements or competitive displacement by longer-lasting therapies
Regulatory pathway evolution for accelerated approvals - FDA scrutiny of surrogate endpoints in rare diseases could delay pipeline assets or require larger confirmatory trials
Reimbursement pressure on ultra-high-cost therapies - payers increasingly challenging $3M+ one-time treatments despite outcomes-based contracts
Pfizer's DMD gene therapy fordadistrogene movaparvovec and other competitive gene therapies targeting overlapping patient populations
CRISPR-based gene editing approaches in preclinical development could offer superior durability and broader mutation coverage
Biosimilar or follow-on exon-skipping therapies eroding market share in legacy products as patents expire post-2030
Negative ROE (-20.3%) and ROA (-7.8%) despite recent profitability indicate accumulated deficit and capital intensity
Negative free cash flow of $400M reflects ongoing manufacturing capex and R&D investments, requiring continued capital markets access
Debt refinancing risk in 2028-2029 when convertible notes mature, dependent on stock price performance and credit conditions
low - Rare disease treatments for life-threatening conditions exhibit minimal demand elasticity regardless of economic conditions. DMD patients require treatment irrespective of GDP growth, and payer coverage (primarily insurance and Medicaid) insulates demand from consumer spending cycles. However, hospital capital budgets and institutional purchasing can face modest pressure during severe recessions.
Rising rates negatively impact valuation multiples for unprofitable/low-margin biotechs as future cash flows are discounted more heavily, though Sarepta's recent profitability reduces this sensitivity. Higher rates increase financing costs for the $950M debt load (0.95 D/E ratio), though the company's $2.95 current ratio provides liquidity cushion. Rate increases also affect M&A valuations and partnership economics. The primary impact is through biotech sector sentiment rather than operational fundamentals.
Moderate - While patient demand is credit-insensitive, Sarepta's ability to finance manufacturing expansion, clinical trials, and potential acquisitions depends on credit market conditions. The company carries convertible debt and may need capital markets access for pipeline development. Tightening credit spreads could increase refinancing costs or limit strategic flexibility, though current liquidity appears adequate through 2027 based on cash burn rates.
growth - Investors focus on ELEVIDYS commercial ramp, pipeline optionality, and rare disease market expansion rather than current profitability or dividends. The 53% revenue growth and recent transition to profitability attract growth-at-reasonable-price investors, while the -82.8% one-year return reflects high volatility typical of clinical-stage biotech. Institutional holders include specialized healthcare funds and biotech-focused investors with high risk tolerance.
high - Biotech stocks exhibit elevated volatility driven by binary clinical and regulatory events. The stock's -82.8% annual decline demonstrates sensitivity to trial results, FDA decisions, and sector rotation. Beta likely exceeds 1.5 relative to broader markets, with event-driven spikes around data readouts and approval decisions. The $1.9B market cap (small-cap biotech) amplifies volatility compared to large-cap pharma.
